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1. Introduction 
The territorial differences in the prevalence of type 1 diabetes mellitus (T1D) around the 
world were previously reported (Amos et al., 1997; Green & Patterson, 2001; Lévy-Marchal, 
2001), but the data were based on the study of juvenile T1D epidemiology, i.e., in patients 
diagnosed with T1D before the age of 15 years. These data became the basis for the 
epidemiological evaluation of the whole T1D patient population. With the relatively limited 
number of children with T1D within the current territory, less effort is required for data 
gathering. Besides, as the age increases, it becomes more difficult to relate a diabetic 
condition to a certain diabetes type (Keen, 1998), thus, making it impossible to directly use 
the diabetes-type data obtained from Primary Care. In modern epidemiological studies, the 
key data concern the age at the time of the diagnosis—patients who were diagnosed before 
the age of 30 years and are insulin-treated, are considered to suffer from T1D.  
1.1 T1D epidemiology in adults  
European researchers have proved that the epidemiological characteristics of T1D in 
children significantly differ from that in young adults (Kyvik et al., 2004). Therefore, 
studying the peculiarities of T1D in adults is a major concern. Furthermore, data on the 
number of diabetic patients usually found in the reports of the healthcare system are 
unstructured according to the history of the disease, and cannot be a source of 
epidemiological information on patients suffering from T1D. Owing to the development of 
the Diabetes Register in Ukraine, it has become possible to conduct analytical comparisons 
and further studies on almost all the T1D adult populations.  
1.2 Diabetes Register  
The Diabetes Register contains individual, structured information on the disease history, 
and has already been used in some epidemiological studies (Khalangot et al., 2009a; 
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Khalangot et al., 2009b; Vaiserman et al., 2009; Khalangot et al., 2009d; Vaiserman & 
Khalangot, 2008). Until recently there was no evidence on age and gender structure of 
patients diagnosed with diabetes mellitus in Ukraine. Neither is there any information on 
risk factors that may influence main aetiological diabetes mellitus type’s incidence, as well 
as development of diabetic complications in Ukraine. Diabetes register is recognized as an 
important tool of diabetes research: it is a fully functioning diabetes register created in 
Ukraine. It includes over 620 000 diabetes patients (2010) and gives a unique possibility to 
analyze the structure of aetiological types, gender and age features, prevalence, trends of 
incidence, risk factors of non-fatal events and mortality among Ukrainian diabetes patients. 
Observational cross-sectional (distribution of diabetes types and treatment, trends of life 
span) and cohort (assessment of mortality risks) epidemiological studies using national 
patient register based on data provided by primary care doctors became possible. The 
register included most of Ukraine’s insulin treated patients, as well as significant part of 
patients receiving oral glucose lowering drugs (OGLD). The insulin-treated patient data 
covers 24 out of 25 Ukrainian regions, meaning that at least nearly all of Ukraine’s T1D 
population is included in the register. According to the Health Ministry data, the total 
amount of patients with known diabetes is 1 048375 (2006), which means that nearly half of 
type 2 diabetes (T2D) patients have yet to be included in the register, which consists of 509 
933 patients, including 37 406 death cases. 
1.3 Register-based diabetes epidemiology studies 
Systematic epidemiological study of main diabetes mellitus (DM) types through analysis of 
electronic population registers has been lasting for over 10 years. Usage of DM population 
registers has become quite advanced in the UK, in particular in Scotland, where by the end 
of 2004, 161 946 diabetics have been included into local diabetic registers which is equal to 
3.2% of the general population. In Scotland, 14 out of 15 healthcare institutions are involved 
in controlling treatment of DM patients. An important aspect is that Scottish DM registers 
include all DM patients, unlike others, that only include patients receiving certain kind of 
treatment. It seems that at the moment, the most advanced and successful Scottish local 
register is Tayside (Boyle et al., 2001; Leese et al., 2006; Morris et al., 1997). It should be 
noted that this relatively small, but constantly functioning register became a source of not 
just “traditional” epidemiologic information concerning prevalence and annual incidence of 
T1D and T2D, dynamics of DM complications frequency, and quality of treatment, which is 
a generalization of routine data from active GPs working in the region, and can be accessed 
through the register’s website (http://www.diabetes-healthnet.ac.uk/), but also of purely 
scientific fundamental data (Doney et al., 2003, 2005; Evans et al., 2005, 2006; Schofield et al., 
2006). A few of these papers have entirely clinically-epidemiological nature, comparing 
mortality among patients with limb amputations depending on presence of DM (Schofield 
et al., 2006 ), or mortality risks depending on certain type of treatment (Evans et al., 2005, 
2006), while others use the register to study genetic characteristics among different 
categories of DM patients (Doney et al., 2003, 2005). One of the researchers of Belgian 
Diabetic Register (BDR) Prof. Frans K. Gorus (Diabetes Research Center, Vrije Universiteit 
Brussel) indicated the possibility of such scientific use of diabetic registers (Gorus, 1996). 
Important epidemiologic, immunologic, and genetic studies of T1D in children and 
adolescents were carried out using BDR (Gorus, 1996;  Vandewalle et al., 1997; Weets et al.,  
2001, 2002).  
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1.3.1 Register-based T2D epidemiology studies 
Some results obtanied by means of studying electronic registers may at first seem unusual 
or paradoxic. In particular our studies of T2D patients (Khalangot et al., 2009b) indicate that 
Hazard Ratios (HRs) of cardiovascular disease (CVD) mortality among extremely obese 
patients [body mass index (BMI) ≥ 35 kg/m2] adjusted for age, smoking and alcohol 
consumption were higher than for overweight patients [BMI 25-29 kg/m2]: HR=1.54 (95% CI 
1.16-2.05) and 1.35 (95% CI 1.15-1.59) among men an women respectively, p<0.01. 
Furthermore, the graph that shows risks of general and CVD mortality for T2D patients 
depending on BMI has the shape of an asymmetric parabola: HRs associated with low and 
normal BMI were significantly higher comparing to those, related to overweight or 
moderate obesity. The above phenomenon partially corresponds to “obesity paradox” that 
has been recently discovered among patients suffering from CVD (Gruberg et al., 2002; 
Curtis et al., 2005) , however in our study this effect concerns T2D patients. An observational 
study that included 25 361 T2D patients showed that glibenclamide treatment is associated 
with much higher risk of general and CVD mortality, comparing to treatment with another 
derivative of sulfonylurea – gliclazide. HRs for total and CVD mortality within the 
glibenclamide patient cohort were 2.57 (95% CI 1.73–3.82) and 2,93 (95%CI 1.83–4.71) 
respectively; (p < 0,001). These data correspond to changes of OGLD distribution and trends 
of life duration among DM patients that we have revealed as well (Khalangot et al., 2009 e). 
Previously, there had been only one study where similar results concerning total mortality 
associated with the use of glibenclamide or gliclazide in a cohort of 568 T2D patients were 
obtained (Monami et al., 2007). Our study broadens this tendency onto CVD mortality.       
1.3.2 Register-based T1D epidemiology studies 
T1D incidence among Ukrainian adults from 1994 till 2004, that we have evaluated 
retrospectively according to the register data,  had a decreasing tendency (Khalangot, 2009). 
Our assessment of T1D incidence dynamics among adults does not confirm the information 
about steady increase of global T1D incidence (Green et al., 2001; Gale, 2002), however these 
studies only concerned child incidence. As Ukraine is also experiencing a rise of DM 
incidence among children, our data can be easily explained by earlier DM manifestation 
among people, who carry the genotype predisposing to T1D. Researchers of Danish DM 
register have recently reported a decrease of DM incidence among young adults. National 
diabetic register of Denmark has collected data on 359 000 DM cases between 1995 and 2006, 
and it includes the total population, diagnosed with DM. This register has recorded a clear 
tendency towards reduction of mortality among DM patients, which has been observed 
since 2003 (Carstensen et al., 2008). We have recently conducted a series of studies as well 
that focused on factors influencing mortality and territorial heterogeneity of T1D in Ukraine 
(Khalangot, 2008; Khalangot et al., 2009 c; 2010). The purpose of these studies (Khalangot et 
al., 2009 d) was also to determine whether the insulin requirement can change systematically 
in T1D patients, and whether this requirement depends on the same factors that determine 
its prevalence. This chapter is mainly a review of these studies.             
2. Methods 
A database with 282,988 records of diabetic patients was developed on the basis of 
epidemiological analysis conducted during the 2005–2006 register verification (01.12.2006). 
To evaluate the completeness of the register data, we compared it to the official 2005 
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Ministry of Health statistical data (Anonymous, 2006). The integrity of the register, i.e., the 
data on the number of patients who have received insulin, was assessed based on the 
information provided by the primary care doctors (district endocrinologists) to the regional 
diabetic registers. Consequently, the regional endocrinologists were responsible for 
updating the data and endorsing it to the central level. Accordingly, by assuming that the 
data were encoded into the regional registers with various degrees of completeness, 
significant limitations were noted in the assessment of the prevalence of insulin-dependent 
diabetes as well as in further epidemiological evaluations. Considering the fact that Ukraine 
has a national, free-of-charge insulin supply to the patients who require it, the Ministry of 
Health data reflect the number of these patients to the fullest extent. However, the 
Ukrainian Ministry of Health receives only non-personalized data that are difficult to verify. 
A comparison of the data from the 2006 Diabetes Register with the 2005 data on the insulin-
treated patients from the Ministry of Health (considered 100%) revealed certain similarities: 
the fraction of the patients included in the register was 91.1%, based on the number of the 
patients according to the Ministry of Health data. However, in the Kharkiv region, only 
58.6% of the Ministry of Health patients were in the register. It was assumed that the 
Kharkiv region data in the register could be incomplete, and hence, was not used in the 
analysis of T1D prevalence among adults.  
2.1 T1D cases selection 
Therefore, the analysis was carried out using the T1D criteria used by the epidemiologists–
researchers for the European diabetes population databases (Kyvik et al., 2004; Soedamah-
Muthu, 2006). The patients were selected based on the following conditions: T1D primary 
care diagnosis; age at the time of being included in the register ≥15 years; place of residence 
and gender; and data on diagnoses before the age of 30 years.  
2.2 T1D prevalence assessment 
The prevalence of T1D in the Ukrainian regions was determined as of the end of 2004. The 
T1D prevalence was calculated using the official data on the adult population of the 
corresponding regions (Anonymous, 2006), and 95% confidence interval (CI) was 
determined using arcsine transformation (Altman et al., ed-s., 2003). Multiple comparisons 
of T1D regional prevalence were subsequently carried out using the modified (Liakh & 
Gurianov, 2004) L. Marascuilo mathematical procedure (Marascuilo, 1966). The MedStat 
statistical package was used for the calculations (Liakh & Gurianov, 2004). Logistic 
regression analysis was used to determine the influence of the explanatory variables on the 
resulting variable (Bland, 2000). For each input variable, we evaluated the estimated logistic 
regression coefficient with the standard error, estimated as the odds ratio (OR) with a CI for 
its actual value and associated p value, and performed a Wald test (testing the null 
hypothesis on the congruency of the OR of the “disease” associated with the increase of this 
variable by 1). We used this information to determine whether each variable was related to 
the outcome of interest, and to quantify the extent of such a relationship (Bland, 2000). The 
Statistica 5.5 (StatSoft Inc., 1999) package was used in this set of calculations.  
2.3 T1D outcomes assessment 
We have evaluated the prevalence of proliferative retinopathy (PR), arterial hypertension 
(AH), and mortality risks in the retrospective cohort of T1D (27,896 patients); these data was 
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published elsewhere (Khalangot et al., 2009c ; 2010). In brief, mortality was assessed using 
the Cox regression model, determining hazard ratios (HRs) and corresponding 95% 
confidence intervals (95% CI). We calculated odds ratios (ORs), and used a logistic 
regression to compare PR and AH.  
2.4 Diabetes-associated antibodies and c-peptide measurements  
A total of  86 T1D patients (42 males and 44 females), with a mean age of 27.5 years (0.86) 
and mean diabetes duration of 10.3 (0.72) years (SE), were randomly selected from four 
regional diabetes-mellitus registers: Chernihivska, Zaporizka; Ivano-Frankivska, and 
Chernivetska. The glutamic acid decarboxylase 65 antibody (GADA), insulin antibody (IA), 
and plasma c-peptide levels were determined using radioimmunoassay (RIA) kits 
(IMMUNOTECH™) after obtaining the patients’ informed consent. The model of the logistic 
regression was used for the multifactor data analysis of GADA, IA, c-peptide persistence, 
OR, and the 95% CI that were determined. The plasma was considered GADA- or IA-
positive, if GADA >1 U/ml or IA >0.4 U/ml, and low c-peptide, if its level was <32.6 
pmol/l. 
3. Register analysis results and discussion 
The analysis of the register of diabetic patients has allowed for the first time to assess the 
adult prevalence of T1D in Ukraine in comparison with important clinical (daily insulin 
dose, mortality, and complications) and some paraclinical (GADA)  characteristics of the 
disease  (Khalangot et al., 2009 c; Khalangot et al., 2009 d; 2010). 
3.1 T1D territorial dissimilarity and clusterization 
The data on adult T1D prevalence in 24 Ukrainian regions (Table 1) indicated territorial 
dissimilarity: chi-square = 648.30, degree of freedom, k =23 (p< 0.001). 
Further multiple comparisons using the modified Marascuilo procedure (Marascuilo, 1966) 
allowed conducting a pairwise assessment of each region. This assessment enabled 
clustering of the regions according to T1D prevalence. The flagged regions that did not 
statistically differ from the minimal level according to prevalence were considered as a 
cluster. This procedure was repeated for the remaining regions as well. The following 
regional clusters were distinguished according to the T1D prevalence: 
Minimal prevalence cluster = AR Crimea, Ivano-Frankivska, Mykolaivska, Odeska, 
Chernivetska, and Luganska regions. 
Intermediate prevalence cluster = Vinnitska, Volynska, Dnipropetrovska, Donetska, 
Zhytomyrska, Zakarpatska, Kirovogradska, Lvivska, Rivnenska, Kievska, Sumska, 
Ternopilska, Poltavska, Khersonska, and Cherkaska regions. 
Maximal prevalence cluster = Zaporizka, Khmelnytska, and Chernigivska 
regions. 
Cases of T1D in each regional cluster were unified and the prevalence was calculated for the 
actual clusters. The T1D prevalence was found to be 6 (5–6), −7 (6–7), and −9 (8–9) per 10,000 
adults, for the minimal, intermediate, and maximal prevalence clusters respectively. A 
comparison of the differences between these groups indicated a high level of confidence (χ2 
= 214.4; p< 0.001), as shown in figure 1. 
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Region (oblast’) 
Gender 
Number of  type1 adult 
diabetic patients Total adult 
population 
males females total, n 
per 10 000 adults
(95 % CI) 
AR Crimea 564 513 1077 5 (5-6) 2 032 600 
Vinnitska 600 464 1064 7 (7-8) 1 440 600 
Volynska 354 271 625 7 (7-8) 844 300 
Dnipropetrovska 1107 1017 2124 7(6-7) 2 992 000 
Donetska 1477 1282 2759 7 (6-7) 4 071 100 
Zhytomyrska 387 339 726 6 (6-7) 1 122 300 
Zakarpatska 354 264 618 6(6-7) 1 000 700 
Zaporizka 732 712 1444 9 (8-9) 1 619 200 
Ivano-Frankivska 351 274 625 5 (5-6) 1 137 500 
Kievska 1476 1514 2990 8 (7-8) 3 804 900 
Kirovogradska 334 327 661 7 (7-8) 913 500 
Luganska 604 623 1227 6 (5-6) 2 127 900 
Lvivska 802 700 1502 7 (6-7) 2 136 000 
Mykolaivska 292 279 571 5 (5-6) 1 041 600 
Odeska 470 438 908 4 (4-5) 2 037 900 
Poltavska 552 464 1016 7 (7-8) 1 345 600 
Rivnenska 355 316 671 7 (7-8) 930 000 
Sumska 408 321 729 7 (6-7) 1 071 700 
Ternopilska 411 297 708 8 (7-8) 925 000 
Kharkivska 597 493 1090  2 479 700 
Khersonska 303 286 589 6 (6-7) 957 000 
Khmelnitska 510 468 978 8 (8-9) 1 163 000 
Cherkaska 408 366 774 7 (6-7) 1 154 600 
Chernivetska 267 177 444 6 (5-6) 746 000 
Chernigyvska 473 403 876 9 (8-9) 1 020 300 
Total 14188 12608 26796  40 115 000 
Table 1. Prevalence of Type 1 Diabetes Mellitus in Adults Diagnosed Before the Age of 30 in 
Ukrainian Regions (Khalangot et al., 2009d)  
3.2 T1D gender assessment 
The fraction of males among the 26,796 adults diagnosed before the age of 30 years 
corresponded to 52.95%, and varied from 49.2% in Luganska to 60.1% in Chernivetska 
regions. In the majority (23 out of 25) of the regions, this fraction was >50%. Comparison of 
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the 25 regions with the fraction of T1D males revealed a certain variation according to the 
territorial attribute (chi-square = 67.70, the degrees of freedom, k =24; p <0.001). However, 
multiple comparisons failed to reveal any distinctions according to the fraction of T1D males 
between the specific regions. Furthermore, it must be noted that there was no increase in the 
female fraction among T1D adults, which is common in the general population. 
It is possible that an increase in the male fraction in this population reflects the 
epidemiological peculiarities of this disease, which have not yet been described by the 
identified (as well as the unknown) factors that could lead to the increase in the mortality 
among males. 
 
 
Note: given Means ± SE (the dot within the box and height of boxes respectively), 95% CI (lines that 
emerge above and below the boxes) 
Fig. 1. Prevalence of Type 1 Diabetes Mellitus Diagnosed in Patients Under the Age of 30 in 
Territorial Clusters of Ukrainian Regions (per 10 000 adults, 95% CI) (Khalangot et al., 2009 d) 
3.3 T1D insulin doses assessment 
The data analysis of the 23,633 T1D patients (Table 2) from the register, who were classified 
according to insulin dose, age, and disease duration, indicated that women have a higher 
average age and disease duration, but lower daily insulin dose, when compared with men. 
 
Number of  T1D 
patients (n) 
Mean age, yrs(SD) 
Mean diabetes duration, 
yrs(SD) 
Mean insulin dose, 
U/day (SD) 
Man 
(12364) 
32.48 (11.60) 14.11 (10.47) 52.03 (18.56) 
Women (11269) 33.38 (12.43) 15.69 (10.99) 49.50 (17.98) 
Total (23633) 32.91 (12,01) 14.86 (10.75) 50.83 (18.33) 
Note: Ǿ (man/women) < 0.001 
Table 2. Average Age, Disease Duration, and Daily Insulin Dose of Type 1 Diabetes Mellitus 
Patients in Ukraine According to the Diabetes Register data (Khalangot et al., 2009 d) 
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3.3.1 T1D insulin doses and diabetes duration 
As the average duration of the disease was found to be 14.86 years, the average daily insulin 
doses were calculated for each year of the duration, from 0 (<1) to 15 years.  
The regression analysis (figure 2) indicated that in this range, the insulin dose rises with the 
increase in the disease duration: 
Insulin (units/day) = 0.7326 × duration (years) + 43.74 (coefficient of linear correlation, R = 
0.899, p < 0.001). 
 
 
 
 
 
Fig. 2. Average (Mean ± SE) daily insulin doses of type 1 diabetes mellitus patients 
depending on the disease duration in the range of 0-15 years (Khalangot et al., 2009 d) 
A further increase in the disease duration in the range of 16–31 years was not accompanied 
by regular changes in the insulin dose. The regular rise of insulin dose, observed with the 
increase in the duration of T1D in adults diagnosed before the age of 30 years, is still an 
unknown phenomenon. However, this phenomenon was observed to correspond to the 
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observation that T1D patients have long-standing insulin secretion at times (the study of c-
peptide level), which was proven by Bonora (Bonora et al., 1984) and confirmed by the 
Diabetes Control and Complications Trial (DCCT). These research efforts uncovered the 
diverse influence of different insulin-therapy patterns on the process described (The DCCT 
Research Group, 1987; 1998). The confirmation of this data with the prospective observation 
was undertaken in Germany (Linn et al., 2003). Our results could be viewed as an indirect 
confirmation of the extended continuation of the β-cell secretion, obtained through the 
cross-sectional treatment data analysis of almost the entire population of T1D patients in 
Ukraine. The standardization of the daily insulin doses, depending on the disease duration, 
enables the necessary quantitative comparisons of the treatments for T1D adult patients. 
3.3.2 T1D insulin doses in territorial clusters 
It would be logical to consider that the rate of decrease in insulin secretion among the T1D 
patients that differs according to the prevalence of such autoimmune disease, as T1D will 
also vary. Table 3 presents the comparisons of the daily insulin doses (median) in all the 
three clusters of the regions selected according to the prevalence of T1D in adults. 
 
Type 1 diabetes prevalence 
cluster 
Insulin doses standardized 
according to diabetes 
duration, median, U/day
95%CI Р 
 
1. minimal 45.89 45.28 - 47.19 < 0.01  (1 vs 3) 
2. intermediate 52 47.61 - 52.78 < 0.05 (1 vs 2) 
3. maximal 56.59 53.33 -57.88 < 0.05 (2 vs 3) 
Note: Number of diabetes duration yearly groups (n) in all clusters is 16. 
Table 3. Comparison of daily insulin doses standardized for every year of disease duration 
in the range of 0-15 years in clusters of regions singled out according to prevalence of 
diabetes mellitus type 1 (Khalangot et al., 2009 d). 
Insulin doses standardized according to the disease duration within the range of 0–15 years 
in the minimal prevalence cluster of T1D prevalence were significantly lower, when 
compared with the intermediate and maximal prevalence clusters. The values in the 
intermediate prevalence cluster were lower than those in the maximal prevalence cluster 
(figure 3, table 3).  
By evaluating the data presented in table 3, it should be noted that the probability 
coefficients (P), in this case, reflect  a relatively small number of the “yearly” groups (n=16) 
in each cluster. If we were to assess the individual data on the insulin dose in each cluster 
without yearly grouping, then the number of cases (n) corresponding to the number of 
patients would greatly increase: 4,658; 14,712 and 2,879 in the minimal, intermediate, and 
maximal prevalence clusters, respectively. The unstandardized according to the diabetes 
duration average doses and their standard deviations (SD) in each of the three clusters, were 
observed to be 46.62 (19.38); 51.54 (17.57); and 55.94 (19.46) units/day, respectively, which 
was found to increase (p < 0.0001) in the clusters with higher T1D prevalence. However, the 
correlation of the insulin dose and the T1D prevalence found in this current region needs to 
be explained. One of the explanations for the difference in the daily insulin doses could be 
that in different Ukrainian regions, the doctors administer different levels of diabetes 
control: the lower dose is explained not only by the lower requirement of insulin by 
patients, but rather by the lower quality of treatment. An alternative explanation could be 
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the higher intensity of the autoimmune process in patients residing in a territory with higher 
T1D prevalence. 
 
 
Fig. 3. Average daily insulin doses of diabetes mellitus type 1 patients depending on the 
disease duration (in the range of 0-15 years) as well as on the territorial cluster, selected 
according to disease prevalence (Khalangot et al., 2009 d) 
3.3.3 Quality of glucose lowering treatment and mean insulin doses in T1D prevalence 
clusters 
Glycated hemoglobin (HbA1c) is considered as the most evident criteria in determining the 
quality of glucose-lowering treatment. We have analyzed and compared the levels of HbA1c 
of 1,288 T1D patients, included in the register. Table 4 shows the average HbA1c levels and 
the daily insulin doses according to the T1D prevalence clusters. 
 
Type1 diabetes 
prevalence cluster 
N Mean HbA1c level, % 
(SD) 
Mean insulin dose, U/day 
(SD) 
1. Minimal 111 8.57 (3.29) 40.91(16.24) 
2. Intermediate 778 8.24 (2,3) 51.5 (14.8) 
3. Maximal 240 9.52 (2.24) 54.79 (18.05) 
Ǿ (1 vs 3)  < 0.01 < 0.001 
Table 4. Average levels of HbA1c (%) and insulin doses (units/day) considering territorial 
clusters with various diabetes type 1 prevalence (Khalangot et al., 2009 d)  
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The level of HbA1c in the maximal prevalence cluster was significantly greater than that in 
the minimal prevalence cluster, which does not support the assumption of lower treatment 
quality in the regions with lower T1D prevalence. Therefore, the alternative explanation 
using the discovered phenomenon remains rather the most likely one. Its confirmation may 
include c-peptide determination as well as the determination of antibodies associated with 
diabetes in patients residing in the Ukrainian territories with different T1D prevalence. 
However, the reason for the heterogenic prevalence of T1D is still unknown.  
3.4 GADA, IA and c-peptide levels in plasma of T1D patients from different prevalence 
clusters 
The GADA and IA levels in children recently diagnosed with T1D are observed to be higher 
in countries with a greater incidence of this disease, such as Sweden, when compared with 
those where the T1D incidence is lower, such as Lithuania (Holmberg et al., 2006). In our 
study, the GADA levels and persistence in patients from the maximal T1D prevalence 
cluster (n=38), were higher than that in patients from the minimal prevalence cluster (n=48): 
14.1±4.6 and 3.2±1.2 U/ml, respectively, mean ± SE = 0.028; OR = 9.66 (3.31–28.17), p< 0.001. 
Adjusting for age, gender, and duration of diabetes affected the results only slightly: OR = 
7.91 (2.44–25.57), p< 0.001. However, the IA and c-peptide levels and their persistence were 
not observed to be associated with T1D prevalence. It should be noted that persistence of IA 
is common only for children with T1D (reviewed by Dib & Gomes, 2009), when our study 
analyzed adults. These data was obtained in 2007 and published earlier elsewhere 
(Khalangot et al., 2009 d). In another series of our studies (unpublished data) conducted in 
2010 on T1D patients (11 from Minimal cluster and 18 from Maximal one) selected in the 
same way, the GADA levels also differed significantly: 0.92 (0.61-3.04) and 24.43 (3.28-61.42) 
U/l, Me , 95% CI, p = 0.003; adjusted for diabetes duration OR = 8.6 (1.1-65.7), p=0.036.  
That is, the chance to have high GADA levels is almost 9 times higher for patients from the 
Maximal cluster as compared to the Minimal cluster, and this ratio was stable during 
repeated trials in these populations of T1D. Thus, the phenomenon of stable GADA 
persistence was discovered among adult T1D patients, residing in Ukraine within the 
maximal prevalence cluster. 
3.5 T1D outcomes assessment in territorial prevalence clusters  
The obtained results allow us to assume that there may be differences in the incidence of 
adverse outcomes of the disease among populations with varying prevalence of T1D. The 
gathered large cohort (29 708 T1D patients) may be viewed as almost complete data on this 
category of patients in Ukraine (Khalangot et al., 2009 c, 2010). It should be noted, that the 
average duration of T1D is low (17.32 years). According to the data from a cross sectional 
study of Swedish National Diabetic Register (NDR), in 1997 the duration of T1D was 23.1 
years and in 2004 it increased to 26.1 years. The criteria for T1D in the NDR study were 
treatment by insulin only and diagnosis before the age of 30 (Eeg-Olofsson et al., 2007), 
which corresponds to criteria used by us. According to the data from one of the regional 
diabetic registers in the US, the average T1D duration in a cohort of patients who were 
diagnosed before 19 years of age exceeded 25 years (Nishimura et al., 2001). 
3.5.1 Main characteristics of T1D patients from the cohort studied   
The number of men in this cohort is greater than the number of women. Men have shorter 
disease duration (P <0,001) and higher levels of blood pressure (BP) (p <0,001), whereas 
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women have slightly higher levels of fasting glycemia (P <0,05). Blindness, cataracts and 
proliferative retinopathy more common for women (P <0,001). During 122,656.9 person-
years (median observation period 4.7 years) 1958 deaths were recorded. The main cause of 
death was kidney failure. Cancer was very insignificant among other causes of death (table 
5) . Possible reason for this phenomenon may be a short life expectancy of patients with 
diabetes. 
 
Characteristics Men Women All 
    
Number of patients, n 15738 13970 29 708 
Mean age, years (SD) 34.35(12.55) 34.61(13.30) 34.47(12.91) 
Body mass index, kg/m2 (SD) 
23.01(3.84) 
n=14331 
23.34(4.37) 
n=12729 
23.16(4.10) 
BP systolic, mm Hg (SD) 126.29(18.75) 125.48(20.81) 125.91(19.75) 
BP diastolic, mm Hg. (SD) 
78.57(10.53) 
n=14298 
77.66(11.38) 
n=12654 
78.15(10.94) 
Fasting blood glucose, mmol/l (SD) 
9.23(2.82) 
n=13747 
9.30(2.87) 
n=12174 
9.26(2.85) 
HbA1c, % (SD) 
8.68(2.53) 
n=1784 
8.83(2.61) 
n=1789 
8.75(2.57) 
Smoking, n (%)* 3223 (20.48) 414(2.96) 3637(12.24) 
Mean T1D duration, years 16.73 17.98 17.32 
Nephropathy treatment, n (%)* 4627(31.42) 4921(37.59) 9548(34.32) 
Cataract, n (%) * 1573(10.68) 2041(15.59) 3614(12.99) 
Proliferative retinopathy, n (%) * 1187(8.06) 1297(9.91) 2484(8.93) 
Blindness, n (%) * 459(3.1) 506(3.9) 965(3.47) 
Follow up period, median, years 4.7 4.73 4.71 
Total mortality cases, n (%) 1149 (100) 809(100) 1958(100) 
CVD mortality, n (%) 266(23.15) 182(22.5) 448(22.88) 
Cancer mortality, n (%) 16(1.39) 7(0.87) 23(1.17) 
Renal failure, n (%) 295(25.67) 262(32.39) 557(28.45) 
DKA and Coma 25(2.18) 36(4.45) 61(3.12) 
Other reasons (%) 344(29.94) 174(21.51) 518(26.46) 
Unknown 203(17.68) 148(18.29) 351(17.93) 
Notes. BP – blood pressure, DKA – diabetic ketoacydosis; 
* - data concerned to 14723 man and 13092 women 
Table 5. Same characteristics of T1D patients’ cohort (Khalangot et al., 2010) 
Life expectancy of T1D patients in Ukraine in 2007, assessed according to age at the time of 
death did not exceed 40.2 yrs (Khalangot, 2008). In UK, according to similar cohort study 
this value is 55 yrs (Soedamah-Muthu et al., 2006), however the British cohort also included 
children, which could influence the assessment of average T1D duration and age at the time 
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of death. Renal failure is the leading cause of death (28.4%) in T1D patient cohort, whereas 
according to a British study of DM patient register containing primary care data, the leading 
cause of death among T1D patients was CVD (Laing et al., 1999). Similar results were 
obtained by a European study EURODIAB (Soedamah-Muthu et al., 2008). Comparison of 
main causes of death according to EURODIAB data and Ukrainian Diabetes Register (UDR) 
data is shown in figure 4. Apparently death from renal failure among T1D patients in 
Ukraine prevails several times over other causes, while in other parts of Europe the main 
cause of death is CVD. It was previously noted by epidemiologists that the main cause of 
death for T1D patients is renal failure (Dorman et al., 1984), however these data were 
relevant in 1960s-1970s. Today’s experts believe that the shift in mortality structure towards 
CVD happened due to intensification of hypotensive therapy and insulin treatment (Maahs 
et al., 2006), therefore the mortality structure of T1D patients that we have revealed when 
analyzing UDR can be assumed to conform to earlier time period of clinical practice.   
 
 
Note: given Means (%) ± SE (the dot within the box and height of boxes respectively), 95% CI (lines that 
emerge above and below the boxes). Data from Ukrainian Diabetes Register given according to 
Khalangot et al., 2010; EURODIAB given according to Soedamah-Muthu et al., 2008. 
Fig. 4. Interval estimation of structure (%) of the main death causes among T1D patients, 
diagnosed before 30 years of age according to EURODIAB data (white boxes) and Ukrainian 
Diabetes Register (black boxes). Death causes: CVD (A); renal  failure (B); DKA or coma (C); 
cancer (D). 
3.5.2 Mortality assesment in territorial T1D prevalence clusters 
To build the regression model we used 1925 deaths recorded among 27 896 patients. We 
have found that the patients living on the territory belonging to the maximal T1D 
prevalence cluster associated with increased risk of total mortality compared with the 
minimal prevalence cluster. In the minimal territorial cluster mortality was 15.68, and in the 
maximal -- 22.64 cases per 1000 person-years of follow up, p < 0.001. The risk (hazard ratio - 
HR) of death from all-cause mortality in patients from  maximal in relation to the the 
minimal cluster was 1.5 (95% CI 1.31-1.79). Adjusting for gender had almost no effect on this 
risk: HRs standardized according to age, gender, and T1D duration for all cause mortality in 
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the maximal T1D prevalence cluster compared to the minimal made up 1.56 (95 % ǿІ 1.33-
1.81), р<0.001, whereas the same value for diabetes-related mortality was 1.5 (95 % ǿІ 1.14-
1.96), р<0.001. The risk of total mortality for patients from the intermediate cluster did not 
differ from the minimal one (fig. 5, 6). 
During the whole period of observation, 57 cases of death from acute T1D complications 
among 27510 patients have been recorded. It has been established, that prevalence of T1D is 
directly associated with the increase of mortality from acute T1D complications (table 6, 
figure 7). Hazard ratios, determined using Cox model of regression, and standartized 
according to gender, duration, and age in maximal territorial cluster of T1D prevalence 
comparing to the minimal cluster, exceeded 5 : HR= 5.25 (95% CI 1.76-15.63), p<0.001.     
 
T1D 
prevalence 
cluster 
Patients, n 
Follow up 
period,  
person years 
Mean 
Follow up, 
years 
SD Death cases, n
Death cases 
per 1000 
person-years 
Minimal 5 769 20 079,52 3.48 1.74 4 0.2 
Intermedial 17 898 77 323,3 4.3 1.69 36 0.47 
Maximal 3 919 17 974,66 4.59 1.79 17 0.95 
Table 6. Mortality related to acute T1D complications (Khalangot et al., 2010) 
 
 
Fig. 5. All cause mortality represented by survival function in minimal, intermediate, and 
maximal clusters of T1D prevalence (Khalangot et al., 2009c)  
3.5.3 Assesment of high blood pressure and proliferative retinopathy prevalence in 
territorial T1D prevalence clusters 
Assessment of arterial hypertension (AH) incidence among patients in regional clusters was 
performed using the same cohort of 27 896 patients. A total of 4159 hypertension cases, or 
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Fig. 6. DM-related mortality represented by survival function in minimal, intermediate, and 
maximal clusters of T1D prevalence (Khalangot et al., 2009c) 
 
 
Fig. 7. Mortality related to acute T1D complications (cumulative survival) in different 
territorial clusters (Khalangot et al., 2010) 
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14.91%, were recorded. The minimal cluster included 691 AH cases (11.79%), maximal 
cluster had 570 cases (14.46%), and intermediate cluster included 2898 AH cases (16.02%). 
The prevalence of AH or proliferative retinopathy (PR) in the maximal or intermediale 
clusters is greater in relation to the minimal one (Table 7, Fig. 8). Hazard ratios were 1.36 
and 1.46 for maximal and intermediale clusters in relation to the minimal cluster, the HR of 
which was considered as 1. Each year the T1D duration increases the risk of having 
hypertension. Adjusting according to gender, age and diabetes duration did not 
significantly change the risk of AH (table 6). Corresponding ORs for AH and PR were 1.36 
(95% ǿІ 1.2-1.54), р<0,001 and 2.04 (95 % ǿІ 1.72-2.41), р<0.001. It was revealed that T1D 
prevalence is directly linked to the increase of all-cause and diabetes-related mortality risks, 
as well as to PR and AH prevalence.  
 
T1D prevalence cluster Patients, n Cases of Arterial 
Hypertension, n
% 95 % ǿI 
Minimal 5860 691 11.8 11.0-12.6 
Intermedial 18095 2898 16.0 15.5-16.6 
Maximal  3941 570 14.5 13.4-15.6 
Table 7. Prevalence of arterial hypertension  in T1D patients in different territorial clusters 
(Khalangot et al., 2009c) 
 
 
Fig. 8. Fraction (%) of patients with proliferative retinopathy (PR) in different clusters of 
T1D prevalene. The levels of PR prevalence (the dot within the box), its standart errors (the 
box height) and 95% CI (lines that emerge) are shown (Khalangot et al., 2009c). 
We have found only one study that compared mortality between populations that differ in 
prevalence of T1D. This was a joint study of epidemiologists from Finland and Japan (Asao 
et al., 2003).  Previously it was known that the incidence and prevalence of T1D in Finland is 
several times higher than in Japan, however mortality is higher among Japanese patients. 
The researchers explain this phenomenon by the fact that Finland was "disturbed" by its 
world's highest incidence of T1D, and because of that the Finnish health care system has 
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long been implementing public programs of relevant quality for treating diabetes (Asao et 
al., 2003). Comparison of our mortality data among patients with T1D in Ukraine (from 15.7 
to 22.6 per 1000 person-years, respectively, in the minimal and maximal prevalence clusters) 
with mortality among patients with juvenile T1D in Japan and Finland (6.07 and 3.52 per 
1000 person-years, respectively), demonstrates a considerably higher mortality in Ukraine 
and the presense of an opposing relationship between the frequency of T1D in compared 
countries and mortality in cohorts of patients with juvenile diabetes. Please note that cited 
Asao et al. study (2003) compared the mortality in cohorts of patients with infantile T1D 
from different countries, while our study compares T1D that develops in patients before the 
age of 30 in the same country. 
4. T1D sybtype may be responsible for the T1D territorial heterogenity in 
Ukraine 
Currently, researchers (eg. Dib & Gomes, 2009) distinguish such subtypes of T1D, as T1A 
(characterized by selective destruction of beta-cells by an autoimmune process that quickly 
leads to absolute insulin deficiency; most common among caucasians), LADA (Latent 
Autoimmune Diabetes in Adults with an onset usually after 35 years of age and 
characterized by slowly developing insulin deficit), and T1B, also called idiopathic (clinical 
course is similar to T1A, but without the autoimmune component). Fulminant diabetes is 
one of the subtypes of T1B. Its is common in asian countries, such as Japan, China, and 
Korea. It is characterized by a very quick progression of acute metabolic decompensation, 
damage of alpha and beta cells of pancreas, and absence of autoimmune disorders. The 
discovered positive relationship between T1D prevalence, exogenic insulin requirement 
level, development of diabetes complications, and mortality does not allow us to associate 
T1D territorial heterogenity with LADA. Furthermore, the increase of GADA persistence in 
T1D patients who reside in regions with higher prevalence of this disease does not allow to 
consider T1B as responsible for this phenomenon. Thus, T1A rather than T1B subtype of 
T1D determines the territorial differences in the risk of developing T1D as well as course 
severity of this autoimmune disease.      
5. Future studies 
Causal link between the territorial distribution of autoimmune T1D in adults and the 
severity of its course and outcomes remains unknown. The recently discovered antibodies 
to the type 8 zinc transporter (ZnT8As) have substantially improved the clinical 
stratification of autoimmune diabetes in adults, demonstrating the link to a more severe 
insulin deficiency (Lampasone et al., 2010). Swedish researchers point out the possibility 
of low zinc content in drinking water as a possible T1D risk factor in children 
(Samuelsson et al., 2010; Haglund et al., 1996). Interestingly, in accordance with our 
preliminary results (unpublished data), there is no shortage of zinc in blood plasma in 
adults without diabetes, residing on territories with high prevalence of T1D, and we have 
even observed an increase of plasma zinc levels among adults with T1D comparing to 
similar patients from the minimal cluster. Plasma zink levels may be low (T2D) or high 
(T1D), zink supplementation may improve glycemic control in the two major types of 
diabetes, however the underlying molecular mechanisms have been elucidated very 
insignificantly (revieved by Jansen et al. , 2009). It is possible that the study of ZnT8As in 
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comparison to the levels of zinc in the environment and human body will provide new 
information about the cause of territorial heterogeneity of T1D. 
6. Conclusions 
We have shown, that the prevalence of T1D in the Ukrainian regions differs substantially. 
The daily insulin dose was found to increase regularly with the duration of the disease. This 
study also revealed a positive relation between T1D prevalence and the daily insulin doses, 
and observed a difference in the blood GADA levels among the T1D adults residing in 
territories with different T1D prevalence. 
A unique feature of this study is that instead of examining the incidence, the prevalence of 
T1D was examined. This can be attributed to the relatively recent development of the 
Ukrainian diabetes-mellitus register (Khalangot & Tronko, 2007). Nevertheless, we believe 
that such an approach enabled us to study virtually the entire Ukrainian T1D population, 
and reveal a positive correlation between T1D prevalence, intensity of insulin treatment, 
hyperglycemia (HbA1c), and GADA levels, and its prevalence in adults. However, an earlier 
study of GADA in children recently diagnosed with T1D did not find any relation between 
GADA positivity and the clinical parameters of the disease (Holmberg, 2006). 
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